American Journal of Transplantation最新文献

筛选
英文 中文
Single-Port Robotic Extraperitoneal Donor Nephrectomy: Technique and Initial Case Series. 单端口机器人腹腔外供肾切除术:技术和初始病例系列。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-03 DOI: 10.1016/j.ajt.2026.07.037
Woo Jin Choi, Alvin C Wee, Dylan Isaacson, Yi-Chia Lin, Mohamed Eltemamy
{"title":"Single-Port Robotic Extraperitoneal Donor Nephrectomy: Technique and Initial Case Series.","authors":"Woo Jin Choi, Alvin C Wee, Dylan Isaacson, Yi-Chia Lin, Mohamed Eltemamy","doi":"10.1016/j.ajt.2026.07.037","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.07.037","url":null,"abstract":"<p><p>Minimally invasive donor nephrectomy is the gold standard for reducing donor morbidity, yet transperitoneal approaches carry inherent risks. The extraperitoneal approach offers a potentially safer alternative. We present our initial experience with Single-Port Robotic Extraperitoneal Donor Nephrectomy (SP-REDN), a novel technique utilizing the da Vinci SP system to navigate the retroperitoneal space through a single 5-cm incision that serves as both the operative port and the graft extraction site. Between September 2025 and March 2026, 13 living donors underwent SP-REDN. Five donors (38.5%) had a history of prior abdominal surgery. Our technique utilizes a muscle-sparing anterior rectus sheath incision in supine position. Mean operative time was 180.5 minutes (SD 42.9), with a mean WIT of 6.2 minutes (SD 6.7). There were no open conversions or immediate complications, and the median hospital stay was 2.0 days (IQR 1.0-2.0). This series demonstrates that SP-REDN has the potential to optimize both donor safety and experience by avoiding peritoneal violation and offering a single-incision approach.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149316360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
To be, or not to be, on insulin for simultaneous kidney-pancreas transplant: Is that the question? 胰肾联合移植需要胰岛素还是不需要:这是一个问题吗?
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-05-25 DOI: 10.1016/j.ajt.2026.05.2291
Robert J. Stratta, Alan C. Farney, Jonathan A. Fridell
{"title":"To be, or not to be, on insulin for simultaneous kidney-pancreas transplant: Is that the question?","authors":"Robert J. Stratta,&nbsp;Alan C. Farney,&nbsp;Jonathan A. Fridell","doi":"10.1016/j.ajt.2026.05.2291","DOIUrl":"10.1016/j.ajt.2026.05.2291","url":null,"abstract":"<div><div>The prevalence of type 2 diabetes mellitus (T2DM) among patients with kidney failure is nearly 40%. The therapeutic paradigm for the management of T2DM in the setting of chronic kidney disease (CKD) has undergone a dramatic evolution in recent years. Progressive CKD decreases the need for exogenous insulin, allowing noninsulin treatments to be more effective in controlling serum glucose levels. Although diet, exercise, weight loss, and behavioral therapy are important factors in diabetes management, several noninsulin alternatives have risen to the forefront, including glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonists, particularly in patients with cardiovascular risk factors. Consequently, many patients with T2DM and stage 4/5 CKD previously taking insulin no longer require it at transplant referral and are not considered for simultaneous kidney-pancreas transplant (SKPT). Given the diabetogenic effects of calcineurin inhibitors and steroids, coupled with the more rapid elimination of endogenous insulin associated with improved renal function posttransplant, many patients are denied access to SKPT although they will predictably become insulin-requiring after kidney transplant alone. To be, or not to be, on insulin should no longer be the key question in the evaluation of patients with CKD and T2DM for SKPT.</div></div><div>The prevalence of type 2 diabetes mellitus (T2DM) among patients with kidney failure is nearly 40%. The therapeutic paradigm for the management of T2DM in the setting of chronic kidney disease (CKD) has undergone a dramatic evolution in recent years. Progressive CKD decreases the need for exogenous insulin, allowing noninsulin treatments to be more effective in controlling serum glucose levels. Although diet, exercise, weight loss, and behavioral therapy are important factors in diabetes management, several noninsulin alternatives have risen to the forefront, including glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonists, particularly in patients with cardiovascular risk factors. Consequently, many patients with T2DM and stage 4/5 CKD previously taking insulin no longer require it at transplant referral and are not considered for simultaneous kidney-pancreas transplant (SKPT). Given the diabetogenic effects of calcineurin inhibitors and steroids, coupled with the more rapid elimination of endogenous insulin associated with improved renal function posttransplant, many patients are denied access to SKPT although they will predictably become insulin-requiring after kidney transplant alone. To be, or not to be, on insulin should no longer be the key question in the evaluation of patients with CKD and T2DM for SKPT.</div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2452-2457"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alpha-gal syndrome: Unrecognized risks of a tick-bite-associated allergy in transplantation and cellular therapy α - gal综合征:移植和细胞治疗中蜱叮咬相关过敏的未被认识的风险。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-07-03 DOI: 10.1016/j.ajt.2026.06.023
Jeremy W. Jacobs, Richard M. Kaufman, Joseph Yossi Schwartz, Erika Hall, Toufik Tahiri, Brian D. Adkins, Victoria Costa, Elizabeth P. Crowe, Lindsay Orton, Deva Sharma, Bipin N. Savani, Kara K. Siegrist, Cosby A. Stone Jr., Garrett S. Booth
{"title":"Alpha-gal syndrome: Unrecognized risks of a tick-bite-associated allergy in transplantation and cellular therapy","authors":"Jeremy W. Jacobs,&nbsp;Richard M. Kaufman,&nbsp;Joseph Yossi Schwartz,&nbsp;Erika Hall,&nbsp;Toufik Tahiri,&nbsp;Brian D. Adkins,&nbsp;Victoria Costa,&nbsp;Elizabeth P. Crowe,&nbsp;Lindsay Orton,&nbsp;Deva Sharma,&nbsp;Bipin N. Savani,&nbsp;Kara K. Siegrist,&nbsp;Cosby A. Stone Jr.,&nbsp;Garrett S. Booth","doi":"10.1016/j.ajt.2026.06.023","DOIUrl":"10.1016/j.ajt.2026.06.023","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Alpha-gal syndrome (AGS) is an immunoglobulin E (IgE)-mediated hypersensitivity to the oligosaccharide galactose-α-1,3-galactose, acquired through tick bites and increasingly recognized as a cause of allergic reactions to mammalian-derived medical products. Every major transplant modality creates distinct conditions under which sensitized patients may encounter alpha-gal, yet AGS knowledge has developed almost entirely outside the transplant literature. In conventional solid organ transplantation, risk arises primarily from perioperative exposures to porcine-derived heparin, gelatin-based hemostatic agents, and other mammalian-derived materials. In xenotransplantation, the well-characterized role of alpha-gal as the principal xenoantigen has driven the development of glycoprotein alpha-galactosyltransferase 1-knockout swine, but the distinct IgE-mediated pathway that defines AGS has received little attention. Hematopoietic stem cell transplantation introduces questions about conditioning-related immune remodeling of preexisting IgE sensitization, rabbit antithymocyte globulin as an underrecognized alpha-gal exposure, and transfusion-related alpha-gal syndrome when group B or AB plasma-containing blood products are transfused to susceptible patients. Cellular therapy manufacturing workflows that use animal-derived ancillary materials represent a further theoretical exposure pathway. Importantly, detectable anti-alpha-gal IgE does not invariably predict clinical reactivity, and the most appropriate clinical approach is risk stratification rather than reflexive exclusion. Generating the evidence base to support such stratification will require collaboration across allergy, transplant, and transfusion medicine.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Alpha-gal syndrome (AGS) is an immunoglobulin E (IgE)-mediated hypersensitivity to the oligosaccharide galactose-α-1,3-galactose, acquired through tick bites and increasingly recognized as a cause of allergic reactions to mammalian-derived medical products. Every major transplant modality creates distinct conditions under which sensitized patients may encounter alpha-gal, yet AGS knowledge has developed almost entirely outside the transplant literature. In conventional solid organ transplantation, risk arises primarily from perioperative exposures to porcine-derived heparin, gelatin-based hemostatic agents, and other mammalian-derived materials. In xenotransplantation, the well-characterized role of alpha-gal as the principal xenoantigen has driven the development of glycoprotein alpha-galactosyltransferase 1-knockout swine, but the distinct IgE-mediated pathway that defines AGS has received little attention. Hematopoietic stem cell transplantation introduces questions about conditioning-related immune remodeling of preexisting IgE sensitization, rabbit antithymocyte globulin as an underrecognized alpha-gal exposure, and transfusion-related alpha-gal syndrome when group B or AB plasma-containing blood products are tra","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2436-2443"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148379961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contraception use differs across solid organ transplant types among women transplanted in reproductive age 在育龄妇女中,不同类型的实体器官移植使用不同的避孕措施。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-07-24 DOI: 10.1016/j.ajt.2026.05.2299
Katherine M. Cooper, Rachael E. Mahle, Kayla Joyal, Mariesa Le, Jay Luther, Lauren D. Feld, Deepika Devuni, Emily Bethea, Eric M. Przybyszewski
{"title":"Contraception use differs across solid organ transplant types among women transplanted in reproductive age","authors":"Katherine M. Cooper,&nbsp;Rachael E. Mahle,&nbsp;Kayla Joyal,&nbsp;Mariesa Le,&nbsp;Jay Luther,&nbsp;Lauren D. Feld,&nbsp;Deepika Devuni,&nbsp;Emily Bethea,&nbsp;Eric M. Przybyszewski","doi":"10.1016/j.ajt.2026.05.2299","DOIUrl":"10.1016/j.ajt.2026.05.2299","url":null,"abstract":"<div><div>The number of reproductive-age solid organ transplantation (SOT) recipients is growing, yet comparative data on contraception use across organ types are limited. We performed a retrospective cohort study of women who underwent first-time liver, kidney, heart, or lung transplantation between the ages of 18 and 45 years from 2015 and 2025 using TriNetX (n = 10 155). Contraception uptake within 2 years was assessed by organ, including patterns of initial contraceptive method and subsequent method changes, and clinical outcomes, including osteoporosis, thromboembolism, and graft rejection, were compared by contraception type. Among 10,155 eligible SOT recipients, 19.9% had documented contraception within 2 years of SOT (heart 27.3%, lung 22.5%, kidney 19.7%, liver 16.8%, <em>P</em> &lt; .001). Combined oral contraception was the most common initial contraception method, followed by depot medroxyprogesterone acetate (DMPA). However, those who started on DMPA were more likely to switch methods. Compared with no contraception, DMPA was associated with increased risk of osteoporosis, hypertension, thrombosis, and graft rejection, whereas estradiol-containing agents were not. Overall, contraception use after SOT was uncommon with very low rates of highly effective options, particularly after liver and kidney transplant. Higher switching and adverse associations with DMPA support early, organ-tailored contraceptive counseling and careful method selection post-SOT.</div></div><div>The number of reproductive-age solid organ transplantation (SOT) recipients is growing, yet comparative data on contraception use across organ types are limited. We performed a retrospective cohort study of women who underwent first-time liver, kidney, heart, or lung transplantation between the ages of 18 and 45 years from 2015 and 2025 using TriNetX (n = 10 155). Contraception uptake within 2 years was assessed by organ, including patterns of initial contraceptive method and subsequent method changes, and clinical outcomes, including osteoporosis, thromboembolism, and graft rejection, were compared by contraception type. Among 10,155 eligible SOT recipients, 19.9% had documented contraception within 2 years of SOT (heart 27.3%, lung 22.5%, kidney 19.7%, liver 16.8%, <em>P</em> &lt; .001). Combined oral contraception was the most common initial contraception method, followed by depot medroxyprogesterone acetate (DMPA). However, those who started on DMPA were more likely to switch methods. Compared with no contraception, DMPA was associated with increased risk of osteoporosis, hypertension, thrombosis, and graft rejection, whereas estradiol-containing agents were not. Overall, contraception use after SOT was uncommon with very low rates of highly effective options, particularly after liver and kidney transplant. Higher switching and adverse associations with DMPA support early, organ-tailored contraceptive counseling and careful method selection post-SOT.</div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2597-2606"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148583184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term renal outcomes in living kidney donors with asymptomatic nephrolithiasis: A 10-year single-center study 无症状肾结石活体肾供者的长期肾脏预后:一项10年单中心研究
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-05-27 DOI: 10.1016/j.ajt.2026.05.2292
Emre Arpali, Levent Özbek, Cihan Karataş, Başak Akyollu, Bilal Günaydin, Erol Demir, Mümin Uzunalan, Badi Rawashdeh, Beje Thomas, Ty Blink Dunn, Burak Kocak
{"title":"Long-term renal outcomes in living kidney donors with asymptomatic nephrolithiasis: A 10-year single-center study","authors":"Emre Arpali,&nbsp;Levent Özbek,&nbsp;Cihan Karataş,&nbsp;Başak Akyollu,&nbsp;Bilal Günaydin,&nbsp;Erol Demir,&nbsp;Mümin Uzunalan,&nbsp;Badi Rawashdeh,&nbsp;Beje Thomas,&nbsp;Ty Blink Dunn,&nbsp;Burak Kocak","doi":"10.1016/j.ajt.2026.05.2292","DOIUrl":"10.1016/j.ajt.2026.05.2292","url":null,"abstract":"<div><div>Nephrolithiasis remains an important consideration in living kidney donor evaluation, but long-term outcomes in carefully selected donors with asymptomatic stones remain incompletely defined. We evaluated renal functional trajectories and postdonation stone recurrence among donors with incidental nephrolithiasis identified during predonation assessment. In this single-center retrospective cohort study, all living kidney donors who underwent nephrectomy between March 2007 and March 2017 under a standardized age-stratified protocol were analyzed. Donors with asymptomatic nephrolithiasis on predonation computed tomography were compared with stone-free donors. Primary endpoints were postdonation stone recurrence and estimated glomerular filtration rate (eGFR; 2021 Chronic Kidney Disease Epidemiology Collaboration equation) at last follow-up. Multivariable and longitudinal mixed-effects models were used to evaluate renal outcomes. Among 1444 approved donors, 52 (3.6%) had asymptomatic nephrolithiasis; 44 were included in the final analytical cohort. No donor developed radiologic recurrence or symptomatic stone events during extended follow-up. Nephrolithiasis was not independently associated with last follow-up eGFR, ≥30% decline in eGFR, or longitudinal renal functional trajectories. Carefully selected donors with small, asymptomatic stones demonstrated favorable long-term outcomes, supporting a risk-stratified approach to donor selection.</div></div><div>Nephrolithiasis remains an important consideration in living kidney donor evaluation, but long-term outcomes in carefully selected donors with asymptomatic stones remain incompletely defined. We evaluated renal functional trajectories and postdonation stone recurrence among donors with incidental nephrolithiasis identified during predonation assessment. In this single-center retrospective cohort study, all living kidney donors who underwent nephrectomy between March 2007 and March 2017 under a standardized age-stratified protocol were analyzed. Donors with asymptomatic nephrolithiasis on predonation computed tomography were compared with stone-free donors. Primary endpoints were postdonation stone recurrence and estimated glomerular filtration rate (eGFR; 2021 Chronic Kidney Disease Epidemiology Collaboration equation) at last follow-up. Multivariable and longitudinal mixed-effects models were used to evaluate renal outcomes. Among 1444 approved donors, 52 (3.6%) had asymptomatic nephrolithiasis; 44 were included in the final analytical cohort. No donor developed radiologic recurrence or symptomatic stone events during extended follow-up. Nephrolithiasis was not independently associated with last follow-up eGFR, ≥30% decline in eGFR, or longitudinal renal functional trajectories. Carefully selected donors with small, asymptomatic stones demonstrated favorable long-term outcomes, supporting a risk-stratified approach to donor selection.</div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2548-2556"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148051237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of endothelial cell antibodies associated with pediatric and adult kidney allograft rejection and assessment of a non-human leukocyte antigen antibody assay 内皮细胞抗体与儿童和成人肾移植排斥反应相关的发现和非hla抗体测定的评估。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-06-09 DOI: 10.1016/j.ajt.2026.05.2304
Carrie L. Butler, Michelle J. Hickey, Meghan H. Pearl, Ying Zheng, David Gjertson, Gemalene Sunga, Lucia Chen, Sitaram Vangala, David Elashoff, Patricia Weng, Erik Lum, Suphamai Bunnapradist, Basmah Abdalla, Phuong-Thu Pham, Julie M. Yabu, Supreet Sethi, Elizabeth Kendrick, Gabriel Danovitch, Nima Nassiri, Jeffrey Veale, Elaine F. Reed
{"title":"Discovery of endothelial cell antibodies associated with pediatric and adult kidney allograft rejection and assessment of a non-human leukocyte antigen antibody assay","authors":"Carrie L. Butler,&nbsp;Michelle J. Hickey,&nbsp;Meghan H. Pearl,&nbsp;Ying Zheng,&nbsp;David Gjertson,&nbsp;Gemalene Sunga,&nbsp;Lucia Chen,&nbsp;Sitaram Vangala,&nbsp;David Elashoff,&nbsp;Patricia Weng,&nbsp;Erik Lum,&nbsp;Suphamai Bunnapradist,&nbsp;Basmah Abdalla,&nbsp;Phuong-Thu Pham,&nbsp;Julie M. Yabu,&nbsp;Supreet Sethi,&nbsp;Elizabeth Kendrick,&nbsp;Gabriel Danovitch,&nbsp;Nima Nassiri,&nbsp;Jeffrey Veale,&nbsp;Elaine F. Reed","doi":"10.1016/j.ajt.2026.05.2304","DOIUrl":"10.1016/j.ajt.2026.05.2304","url":null,"abstract":"&lt;div&gt;&lt;div&gt;To investigate the role of non-human leukocyte antigen (HLA) antibodies in kidney allograft rejection, we developed a non-HLA antibody Luminex assay to identify kidney transplant recipients at risk of allograft rejection. Protein microarray analysis (&gt;1.5 fold; &lt;em&gt;P&lt;/em&gt; &lt; .05) of 16 rejection-positive, endothelial cell crossmatch-positive patients identified 135 non-HLA antigens. From these, 12 novel antigens were prioritized for their membrane localization, kidney expression, and identification in more than one patient. A Luminex assay including these 12 novel antigens as well as 67 previously reported non-HLA antigens was developed and validated in 2 independent kidney transplant cohorts: an adult kidney cohort (n = 160) and a longitudinal pediatric kidney cohort (n = 62). Relative risk ratio analysis identified 3 non-HLA antibodies associated with rejection in the adult cohort (&lt;em&gt;P&lt;/em&gt; &lt; .05) and 15 associated with rejection in the pediatric cohort (&lt;em&gt;P&lt;/em&gt; &lt; .1), including 8 with strong significance (&lt;em&gt;P&lt;/em&gt; &lt; .05). A correlation matrix identified 4 non-HLA antibodies that were independently associated with rejection (PLA2R1, CSF2, GSTT1, LGALS8). Decision tree analysis predicted rejection 71% of the time. Four of 12 novel antigens were corroborated in the validation cohorts. CSF2 was associated with acute peritubular capillaritis (ptc) and acute intimal arteritis (&lt;em&gt;P&lt;/em&gt; &lt; .05). These findings suggest that non-HLA antibodies are associated with an increased risk of rejection in kidney transplant recipients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;To investigate the role of non-human leukocyte antigen (HLA) antibodies in kidney allograft rejection, we developed a non-HLA antibody Luminex assay to identify kidney transplant recipients at risk of allograft rejection. Protein microarray analysis (&gt;1.5 fold; &lt;em&gt;P&lt;/em&gt; &lt; .05) of 16 rejection-positive, endothelial cell crossmatch-positive patients identified 135 non-HLA antigens. From these, 12 novel antigens were prioritized for their membrane localization, kidney expression, and identification in more than one patient. A Luminex assay including these 12 novel antigens as well as 67 previously reported non-HLA antigens was developed and validated in 2 independent kidney transplant cohorts: an adult kidney cohort (n = 160) and a longitudinal pediatric kidney cohort (n = 62). Relative risk ratio analysis identified 3 non-HLA antibodies associated with rejection in the adult cohort (&lt;em&gt;P&lt;/em&gt; &lt; .05) and 15 associated with rejection in the pediatric cohort (&lt;em&gt;P&lt;/em&gt; &lt; .1), including 8 with strong significance (&lt;em&gt;P&lt;/em&gt; &lt; .05). A correlation matrix identified 4 non-HLA antibodies that were independently associated with rejection (PLA2R1, CSF2, GSTT1, LGALS8). Decision tree analysis predicted rejection 71% of the time. Four of 12 novel antigens were corroborated in the validation cohorts. CSF2 was associated with acute peritubular capillaritis (ptc) and acute inti","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2497-2510"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148209490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Viewpoint on donor-derived cell-free DNA: Context of use and clinical utility are key 对供体来源的无细胞DNA的观点:使用背景和临床应用是关键。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-07-14 DOI: 10.1016/j.ajt.2026.07.004
Klemens Budde, Georg A. Böhmig, Philip F. Halloran, Abhinav Humar, Anthony Langone, Maarten Naesens, Michael Oellerich, Rommel Ravanan, Tariq Shah, Ekkehard Schuetz, Louise Benning
{"title":"Viewpoint on donor-derived cell-free DNA: Context of use and clinical utility are key","authors":"Klemens Budde,&nbsp;Georg A. Böhmig,&nbsp;Philip F. Halloran,&nbsp;Abhinav Humar,&nbsp;Anthony Langone,&nbsp;Maarten Naesens,&nbsp;Michael Oellerich,&nbsp;Rommel Ravanan,&nbsp;Tariq Shah,&nbsp;Ekkehard Schuetz,&nbsp;Louise Benning","doi":"10.1016/j.ajt.2026.07.004","DOIUrl":"10.1016/j.ajt.2026.07.004","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Recently, the Sensitization in Transplantation: Assessment of Risk (STAR) group of the American Society of Transplantation and the American Society for Histocompatibility and Immunogenetics published a position on donor-derived cell-free DNA (dd-cfDNA), followed by a letter emphasizing its specificity for rejection and a response. We aim to add personal and methodological perspectives on diagnostic metrics to an ongoing discussion focusing on the context of use and clinical utility of dd-cfDNA across different clinical scenarios. Particularly, we discuss the implications of the overall moderate specificity (approximately 80%) in publications. We argue that the transplant community would benefit by shifting descriptive diagnostic metrics to clinical utility within well-defined contexts of use. Consequently, we consider predictive values and likelihood ratios, which incorporate sensitivity as well—more conclusive measures for clinical medicine. To guide clinicians in adopting this emerging biomarker, we provide a broader overview of the literature focused on kidney transplantation, discuss diagnostic test metrics and society positions, and discuss its added value for detecting graft injury within routine decisional frameworks. We emphasize the need for rigorous cost-benefit assessments across different prevalence scenarios and graft pathologies, necessary for assigning the correct diagnostic interpretation and for aiding in the optimal treatment. We firmly believe that more studies, preferentially interventional, with clear outcome endpoints should be initiated to clarify the full potential of dd-cfDNA.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;Recently, the Sensitization in Transplantation: Assessment of Risk (STAR) group of the American Society of Transplantation and the American Society for Histocompatibility and Immunogenetics published a position on donor-derived cell-free DNA (dd-cfDNA), followed by a letter emphasizing its specificity for rejection and a response. We aim to add personal and methodological perspectives on diagnostic metrics to an ongoing discussion focusing on the context of use and clinical utility of dd-cfDNA across different clinical scenarios. Particularly, we discuss the implications of the overall moderate specificity (approximately 80%) in publications. We argue that the transplant community would benefit by shifting descriptive diagnostic metrics to clinical utility within well-defined contexts of use. Consequently, we consider predictive values and likelihood ratios, which incorporate sensitivity as well—more conclusive measures for clinical medicine. To guide clinicians in adopting this emerging biomarker, we provide a broader overview of the literature focused on kidney transplantation, discuss diagnostic test metrics and society positions, and discuss its added value for detecting graft injury within routine decisional frameworks. We emphasize the need for rigorous cost-benefit assessments across different prevalence scenarios an","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2444-2451"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148441128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Will human-animal chimeras solve the organ shortage problem? 人兽嵌合体能解决器官短缺问题吗?
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-09-11 DOI: 10.1016/j.ajt.2026.09.019
FADI G. LAKKIS
{"title":"Will human-animal chimeras solve the organ shortage problem?","authors":"FADI G. LAKKIS","doi":"10.1016/j.ajt.2026.09.019","DOIUrl":"10.1016/j.ajt.2026.09.019","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2421-2422"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiomic analyses in xenotransplantation: Hypothesis generation and the path toward precision diagnostics 异种移植的多组分析:假设的产生和精确诊断的途径
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-09-23 DOI: 10.1016/j.ajt.2026.09.027
Joseph M. Ladowski, Aurélie Sannier, Alexandre Loupy, Raphael P.H. Meier
{"title":"Multiomic analyses in xenotransplantation: Hypothesis generation and the path toward precision diagnostics","authors":"Joseph M. Ladowski,&nbsp;Aurélie Sannier,&nbsp;Alexandre Loupy,&nbsp;Raphael P.H. Meier","doi":"10.1016/j.ajt.2026.09.027","DOIUrl":"10.1016/j.ajt.2026.09.027","url":null,"abstract":"<div><div>Since the first successful allograft in 1954, the field has sought a method to monitor the delicate balance between immunosuppression and graft function. Over the last 20 years, multiomic approaches have provided increasingly detailed molecular characterization of the immunologic and physiologic processes underlying graft injury. Xenotransplantation, now in its clinical infancy, has been a rapid adopter of multiomic analysis and benefited from lessons learned in allotransplantation. In our first edition of the <em>AJT XenoPulse</em>, we reviewed the progress made in living recipients and the clinical applications of xenotransplantation across cardiac, renal, and hepatic grafts. This second edition summarized the use of multiomics as a hypothesis-generating tool to guide next-generation donor-pig design and adjust immunosuppression, while exploring its contribution to the diagnosis of xenograft rejection. Across organs, emerging studies highlighted prominent innate immune responses and illustrated how tools developed in allotransplantation may need to be adapted to the cross-species setting. These findings are beginning to define a path toward integrated, xeno-specific diagnostics for clinical monitoring and trial design, although most signatures remain associative and will require analytical and clinical validation.</div></div><div>Since the first successful allograft in 1954, the field has sought a method to monitor the delicate balance between immunosuppression and graft function. Over the last 20 years, multiomic approaches have provided increasingly detailed molecular characterization of the immunologic and physiologic processes underlying graft injury. Xenotransplantation, now in its clinical infancy, has been a rapid adopter of multiomic analysis and benefited from lessons learned in allotransplantation. In our first edition of the <em>AJT XenoPulse</em>, we reviewed the progress made in living recipients and the clinical applications of xenotransplantation across cardiac, renal, and hepatic grafts. This second edition summarized the use of multiomics as a hypothesis-generating tool to guide next-generation donor-pig design and adjust immunosuppression, while exploring its contribution to the diagnosis of xenograft rejection. Across organs, emerging studies highlighted prominent innate immune responses and illustrated how tools developed in allotransplantation may need to be adapted to the cross-species setting. These findings are beginning to define a path toward integrated, xeno-specific diagnostics for clinical monitoring and trial design, although most signatures remain associative and will require analytical and clinical validation.</div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2425-2428"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149022480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenomic landscape of the T cell repertoire after human lung transplantation and its clinical relevance 人肺移植后T细胞库的免疫基因组景观及其临床意义。
IF 8.1 2区 医学
American Journal of Transplantation Pub Date : 2026-11-01 Epub Date: 2026-06-17 DOI: 10.1016/j.ajt.2026.06.009
Wenyu Jiao, Yufeng Shen, Katherine D. Long, Tyla Young, Constanza Bay Muntnich, Adriana Prada Rey, Morcel Khwajazadah, Joshua H. Wang, Vineetha Mohan, Kortney Rogers, Arnold Valena, Joseph Costa, Luke Benvenuto, Joshua Sonett, Philippe Lemaitre, Frank D’Ovidio, Selim Arcasoy, Jianing Fu
{"title":"Immunogenomic landscape of the T cell repertoire after human lung transplantation and its clinical relevance","authors":"Wenyu Jiao,&nbsp;Yufeng Shen,&nbsp;Katherine D. Long,&nbsp;Tyla Young,&nbsp;Constanza Bay Muntnich,&nbsp;Adriana Prada Rey,&nbsp;Morcel Khwajazadah,&nbsp;Joshua H. Wang,&nbsp;Vineetha Mohan,&nbsp;Kortney Rogers,&nbsp;Arnold Valena,&nbsp;Joseph Costa,&nbsp;Luke Benvenuto,&nbsp;Joshua Sonett,&nbsp;Philippe Lemaitre,&nbsp;Frank D’Ovidio,&nbsp;Selim Arcasoy,&nbsp;Jianing Fu","doi":"10.1016/j.ajt.2026.06.009","DOIUrl":"10.1016/j.ajt.2026.06.009","url":null,"abstract":"<div><div>Long-term lung transplant survival is limited by rejection and infection, processes governed by T cells, the posttransplant dynamics of which are poorly defined. Using flow cytometry and T cell receptor (TCR) sequencing of serial bronchoalveolar lavage (BAL) and peripheral blood samples, we monitored T cell chimerism, phenotypes, and clonotypic dynamics in a small cohort of lung transplant recipients. We identified alloreactive clones via mixed lymphocyte reaction/TCR sequence pairing and microbial-reactive clones via database matching. We found a recipient-derived tissue-resident memory T cell repertoire progressively established in BAL, stabilized by preexisting, multitissue-shared clones. Clonal graft–blood overlap was significantly mediated by CD8<sup>+</sup> nonalloreactive recipient T cells of multitissue origin. During infection, pathogen-specific clones expanded in BAL, enriched within the nonalloreactive repertoire. A higher host-vs-graft to graft-vs-host T cell ratio was associated with accelerated recipient repopulation, and enrichment of host-vs-graft clones in BAL was associated with early rejection and pulmonary dysfunction. Our exploratory findings provide novel insight into tissue-resident memory T cell establishment and specialization after lung transplantation and highlight TCR features that warrant further validation as potential correlates of graft outcomes.</div></div><div>Long-term lung transplant survival is limited by rejection and infection, processes governed by T cells, the posttransplant dynamics of which are poorly defined. Using flow cytometry and T cell receptor (TCR) sequencing of serial bronchoalveolar lavage (BAL) and peripheral blood samples, we monitored T cell chimerism, phenotypes, and clonotypic dynamics in a small cohort of lung transplant recipients. We identified alloreactive clones via mixed lymphocyte reaction/TCR sequence pairing and microbial-reactive clones via database matching. We found a recipient-derived tissue-resident memory T cell repertoire progressively established in BAL, stabilized by preexisting, multitissue-shared clones. Clonal graft–blood overlap was significantly mediated by CD8<sup>+</sup> nonalloreactive recipient T cells of multitissue origin. During infection, pathogen-specific clones expanded in BAL, enriched within the nonalloreactive repertoire. A higher host-vs-graft to graft-vs-host T cell ratio was associated with accelerated recipient repopulation, and enrichment of host-vs-graft clones in BAL was associated with early rejection and pulmonary dysfunction. Our exploratory findings provide novel insight into tissue-resident memory T cell establishment and specialization after lung transplantation and highlight TCR features that warrant further validation as potential correlates of graft outcomes.</div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"26 11","pages":"Pages 2524-2535"},"PeriodicalIF":8.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13403488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148269411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书